TFPI-2 functions as a potent inhibitor of plasmin and down-regulates plasmin-mediated proteolysis of ECM; consequently, up-regulation of TFPI-2 counteracts the ECM degradation by cancer cells [82, 83]. The gene discussed is TFPI2; the disease is cancer.